Project LiBRha aims to improve pediatric STS diagnosis and treatment through comprehensive molecular testing and liquid biopsy integration. The initiative involves 18 centers and partnerships with the ...
SEATTLE — Molecular testing has been widely integrated into mainstream healthcare, and its use is increasing in dermatology. It can help differentiate between skin conditions, for example, as some ...
A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for ...
CT screening for lung cancer could save countless lives, but low participation rates have led to some eyebrow-raising proposals. Molecular methods, touted by those with a vested interest, promise to ...
Molecular testing, including chromosomal microarray analysis, distinguishes between aggressive and indolent kidney cancer subtypes, aiding in accurate diagnosis. Accurate diagnosis is critical for ...
Ramez N. Eskander, MD, discusses the heterogenous nature of endometrial cancer and molecular testing being used to identify appropriate patients for specific treatments. He also highlights what study ...
Certain serious fungal infections occur in regions of the United States with specific environments and are often tied to soil exposure. These infections can affect both healthy and immunocompromised ...
IVDR: where are we now in molecular testing? How IVDR implementation is progressing in molecular biology laboratories in different European countries IVDR, the new EU legislation for in-vitro ...
Zacks Investment Research on MSN
OraSure files for FDA review of molecular self-test & Colli-Pee device
OraSure TechnologiesOSUR recently announced that it submitted two applications to the FDA seeking approval for its two new at ...
The Eonis™ Q system from Revvity is an innovative dry PCR workflow that simplifies and streamlines molecular testing for SMA and SCID. It comprises the compact Eonis™ Q96 instrument, stable and ...
As we look ahead to 2026, we are continuing to execute on our strategy with purpose and momentum to create value for all our stakeholders.” OTI’s rapid self-test for CT/NG is built on the Sherlock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results